OBJECTIVE: Aim of our study was to analyze the influence of @entity8277 sensitization on the course of controlled ovarian stimulation in the program of assisted reproduction and to identify the availability of ovarian response improvement due to the reduced production of intraovarian @entity3800 . Further we tried to identify the preventive influence of @entity2449 on development of @entity43 . DESIGN: Prospective randomized controlled study of 172 @entity1 involved in the assisted reproduction program from May 2000 to December 2001. SETTING: Centre of Assisted Reproduction, Department of Gynecology and Obstetrics, Medical Faculty, Masaryk University and University Hospital, Brno. MATERIAL AND METHODS: @entity1 undergoing the ovarian stimulation with increased risk of development of @entity43 due to the @entity3610 were included in the study and randomized to two groups. (1) @entity1 in the first group used the @entity8277 sensitizing drug @entity2449 together with gonadotropins, and (2) @entity1 in the second group underwent the classic stimulation protocol alone. The control group (3) consisted of @entity1 with intact ovarian function and different @entity249 factor. Complex hormonal status was assessed before the treatment initiation and the level of @entity3800 in the follicular fluid was investigated in all @entity1 . RESULTS: @entity2449 during gonadotropin stimulation has significantly reduced the risk of @entity43 in @entity1 with @entity3610 . Significantly lower intraovarian @entity342 levels were documented in comparison to @entity1 without @entity2449 and also when compared to @entity1 with intact ovarian function. @entity2449 had also significantly reduced @entity53 blood levels at the day of hCG application without significant influence on the number of obtained oocytes. CONCLUSIONS: The risk of @entity43 development was significantly decreased in @entity1 with @entity3610 in consequence to insulin receptors sensitization.

[Importance of sensitization of insulin receptors in the prevention of XXXX ].

@entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian hyperstimulation syndrome'] @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'Women'] @entity3610 :: ('MESH:D011085', 'Disease') :: ['polycystic ovarian syndrome', 'PCOS'] @entity249 :: ('MESH:D007246', 'Disease') :: ['infertility'] @entity8277 :: ('3643', 'Gene') :: ['insulin receptor'] @entity53 :: ('MESH:D004958', 'Chemical') :: ['estradiol'] @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen'] @entity3800 :: ('MESH:D000728', 'Chemical') :: ['androgens'] @entity2449 :: ('MESH:D008687', 'Chemical') :: ['Metformin', 'metformin']
@entity43 :: (MESH:D010051,Disease) :: ['ovarian hyperstimulation syndrome']
